Nasser Hanna
Expertise in
21
conditions

Dr. Nasser Hanna

Oncology
Office
535 Barnhill Dr Ste 473, 
Indianapolis, IN 
Expertise in
21
conditions
Office
535 Barnhill Dr Ste 473, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nasser Hanna is an Oncologist in Indianapolis, Indiana. Dr. Hanna is highly rated in 21 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Orchiectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 156 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health North Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
535 Barnhill Dr Ste 473, Indianapolis, IN 46202
Other Locations
Univ. Radiation Oncology Associates Inc.
535 Barnhill Dr, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Imprime PGG, MK-3475
Study Phase: Phase 1/Phase 2
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Study Phase: Phase 2
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Osimertinib, Ramucirumab
Study Phase: Phase 2
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
Enrollment Status: Terminated
Publish Date: February 13, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
Enrollment Status: Terminated
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Pemetrexed, Atezolizumab, Bevacizumab
Study Phase: Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse
Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse
Enrollment Status: Completed
Publish Date: August 08, 2018
Intervention Type: Genetic
View 6 Less Clinical Trials

155 Total Publications

Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review.
Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review.
Journal: Clinical lung cancer
Published: June 30, 2025
Similar Doctors
Expertise in
20
conditions
Dr. Lawrence Einhorn
Oncology
Expertise in
20
conditions
Dr. Lawrence Einhorn
Oncology

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (1.3 miles away)
317-274-3515
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Einhorn is an Oncologist in Indianapolis, Indiana. Dr. Einhorn is highly rated in 20 conditions, according to our data. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Orchiectomy, and Bone Marrow Transplant.

Expertise in
18
conditions
Dr. Patrick Loehrer
Oncology
Expertise in
18
conditions
Dr. Patrick Loehrer
Oncology

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (1.3 miles away)
317-278-7418
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patrick Loehrer is an Oncologist in Indianapolis, Indiana. Dr. Loehrer is highly rated in 18 conditions, according to our data. His top areas of expertise are Thymic Epithelial Tumor, Colorectal Cancer, Pancreatic Cancer, Pancreaticoduodenectomy, and Thymectomy.

Bryan Schneider
Expertise in
44
conditions
Dr. Bryan Schneider
Oncology
Expertise in
44
conditions
Dr. Bryan Schneider
Oncology

IU Health Simon Cancer Center

1030 W Michigan St, 
Indianapolis, IN 
 (1.3 miles away)
317-944-0920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bryan Schneider is an Oncologist in Indianapolis, Indiana. Dr. Schneider is highly rated in 44 conditions, according to our data. His top areas of expertise are Breast Cancer, Thymic Epithelial Tumor, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hanna's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile